Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732560 · ClinicalTrials.gov registry record
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 600
- Enrollment target
NCT03732560 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 600 participants.
The verdict
NCT03732560 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
Study Summary
The goal of this study is to describe patient characteristics, treatment outcomes and adverse events for patients with metastatic melanoma testing positive for PD-L1 expression treated first line (1L) with either nivolumab and ipilimumab in combination (NIVO + IPI) or nivolumab (NIVO) monotherapy
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2021-03-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732560
The ClinicalTrials.gov registry entry for NCT03732560 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03732560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03732560 about?
NCT03732560 is a clinical study titled "A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US". The goal of this study is to describe patient characteristics, treatment outcomes and adverse events for patients with metastatic melanoma testing positive for PD-L1 expression treated first line (1L) with either nivolumab and ipilimumab in combination (NIVO + IPI) or nivolumab (NIVO) monotherapy
What is the current status of trial NCT03732560?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2018-07-31. Estimated completion is 2021-03-25.
What interventions are being tested in trial NCT03732560?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03732560?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.